In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

The Impact Of COVID-19 On Clinical Trials

Clinical trials for therapeutic areas aside from COVID-19 are experiencing disruptions and delays as social distancing measures and travel restrictions are implemented across the world.

Clinical Trials Coronavirus COVID-19 Research and Development Strategies

Latest From Market Intelligence

Dealmaking Quarterly Statistics, Q3 2020

During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.

Deals Market Intelligence

Financing Quarterly Statistics, Q3 2020

During Q3, biopharmas brought in an aggregate $36.6bn in financing and device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.

Deals Market Intelligence

Conducting Clinical Trials With CROs: Three Common Risks

Clinical trial sponsors can obtain valuable support from contract research organizations (CROs) but nonetheless remain liable for the conduct of their trials. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, share tips to protect against common problems that can arise during the course of clinical trials.

Business Strategies Clinical Trials

Deals In Depth: September 2020

Seattle Genetics and Merck penned an agreement to globally develop and commercialize (on a co-exclusive basis) Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate in Phase II trials for breast cancer and other solid tumors. The deal has a potential value of over $4bn. While Gilead Sciences entered into a definitive agreement to acquire Immunomedics Inc. for $88 per share in cash, or approximately $21bn. The transaction is expected to close in Q4 2020. Financing reached $14.6bn in biopharma, $824m in devices and $1.9bn in diagnostics.

Deals Market Intelligence

Deals Shaping The Medical Industry, September 2020

This month’s column covers deals announced in September 2020. Data provided by Biomedtracker

Commercial Companies

Riding The Tailwind Of Healthtech Through The Pandemic And Beyond

VC investors and medtech strategists alike at APACMed’s 2020 virtual conference agreed that the challenges presented by COVID-19 have given healthtech a higher profile and accelerated the arrival of health system workflow improvements.

Asia Pacific Singapore
See All
UsernamePublicRestriction

Register